Compare Stocks

Date Range: 

 Vertex PharmaceuticalsTakeda PharmaceuticalBayer AktiengesellschaftRegeneron PharmaceuticalsAlexion Pharmaceuticals
SymbolNASDAQ:VRTXNYSE:TAKOTCMKTS:BAYRYNASDAQ:REGNNASDAQ:ALXN
Price Information
Current Price$185.09$17.15$13.74$646.51$182.50
50-Day Moving Average$195.78$16.81$14.13$630.67$182.82
52-Week Low$182.60$15.30$11.65$441.00$99.91
52-Week High$280.99$19.97$17.34$686.62$187.45
MarketRank™
Overall Score2.81.72.32.51.9
Analysis Score4.30.03.32.41.1
Community Score5.03.94.34.55.0
Dividend Score0.03.32.50.00.0
Ownership Score3.30.00.03.31.7
Earnings & Valuation Score1.31.31.32.51.9
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyHold
Consensus Price Target$266.61N/A$60.00$700.69$161.93
% Upside from Price Target44.04% upsideN/A336.68% upside8.38% upside-11.27% downside
Trade Information
Market Cap$48.02 billion$54.27 billion$53.99 billion$69.15 billion$40.34 billion
Beta0.631.051.270.161.25
Average Volume2,019,5422,683,875451,363863,9513,309,941
Sales & Book Value
Annual Revenue$6.21 billion$30.17 billion$47.29 billion$8.50 billion$6.07 billion
Price / Sales7.741.801.148.146.65
Cashflow$9.40 per share$3.68 per share$5.77 per share$33.19 per share$22.81 per share
Price / Cash19.704.662.3819.488.00
Book Value$33.41 per share$15.42 per share$8.92 per share$102.91 per share$53.24 per share
Price / Book5.541.111.546.283.43
Profitability
Net Income$2.71 billion$3.53 billion$-11,988,440,000.00$3.51 billion$603.40 million
EPS$9.03$1.98$1.82$28.66$11.60
Trailing P/E Ratio24.4211.75N/A11.6159.64
Forward P/E Ratio16.2418.246.8014.6613.15
P/E Growth1.77N/A3.320.770.93
Net Margins29.80%14.69%-6.30%50.11%10.89%
Return on Equity (ROE)29.73%13.00%19.76%50.43%23.43%
Return on Assets (ROA)21.96%5.11%5.37%33.56%15.06%
Dividend
Annual PayoutN/A$0.68$0.41N/AN/A
Dividend YieldN/A3.97%2.98%N/AN/A
Three-Year Dividend GrowthN/A6.41%N/AN/AN/A
Payout RatioN/A34.34%22.53%N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.06%0.83%1.20%0.13%0.19%
Current Ratio4.61%1.51%1.16%3.57%4.52%
Quick Ratio4.43%1.03%0.80%3.04%3.96%
Ownership Information
Institutional Ownership Percentage88.63%2.99%0.11%82.31%82.94%
Insider Ownership Percentage0.70%N/AN/A11.84%4.03%
Miscellaneous
Employees3,4002,02199,5389,1233,837
Shares Outstanding259.43 million3.16 billion3.93 billion106.96 million221.02 million
Next Earnings Date11/4/2021 (Estimated)11/4/2021 (Estimated)11/2/2021 (Estimated)11/4/2021 (Estimated)N/A
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Alexion Must Face Claims Of Stalling On Drug After MergerAlexion Must Face Claims Of Stalling On Drug After Merger
law360.com - September 3 at 1:31 AM
AZ/Alexion’s Wilson disease drug hits the mark in phase III, calming post-merger nervesAZ/Alexion’s Wilson disease drug hits the mark in phase III, calming post-merger nerves
bioworld.com - August 27 at 9:13 AM
Ascendis’ weekly GHD treatment wins FDA go-aheadAscendis’ weekly GHD treatment wins FDA go-ahead
bioworld.com - August 27 at 3:52 AM
ALXN1840 FoCus Phase III trial in Wilson disease met primary endpoint demonstrating improvementALXN1840 FoCus Phase III trial in Wilson disease met primary endpoint demonstrating improvement
miragenews.com - August 26 at 7:08 AM
Were Hedge Funds Right About Alexion Pharmaceuticals, Inc. (ALXN)?Were Hedge Funds Right About Alexion Pharmaceuticals, Inc. (ALXN)?
finance.yahoo.com - August 9 at 2:07 PM
Alexion Pharmaceuticals Inc ALXN-MXAlexion Pharmaceuticals Inc ALXN-MX
cnbc.com - July 24 at 10:08 PM
AstraZeneca Wraps Its Massive Alexion Buyout — Is AZN Stock A Buy Or Sell?AstraZeneca Wraps Its Massive Alexion Buyout — Is AZN Stock A Buy Or Sell?
finance.yahoo.com - July 23 at 3:38 PM
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
finance.yahoo.com - July 22 at 5:32 PM
ALXN vs. TECH: Which Stock Is the Better Value Option?ALXN vs. TECH: Which Stock Is the Better Value Option?
finance.yahoo.com - July 21 at 3:06 PM
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) – Experts See The Stock A Different Way TodayAlexion Pharmaceuticals Inc. (NASDAQ:ALXN) – Experts See The Stock A Different Way Today
marketingsentinel.com - July 20 at 6:09 PM
Alexions Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal LoomsAlexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms
feeds.benzinga.com - July 20 at 3:16 PM
Moderna stock has taken on a life of its own ahead of S&P 500 entranceModerna stock 'has taken on a life of its own' ahead of S&P 500 entrance
msn.com - July 20 at 1:07 PM
Alexion Pharmaceuticals Inc. [ALXN] is 14.86% higher this YTD. Is it still time to buy?Alexion Pharmaceuticals Inc. [ALXN] is 14.86% higher this YTD. Is it still time to buy?
dbtnews.com - July 20 at 1:07 PM
Alexion Pharmaceuticals Stock Appears To Be Modestly OvervaluedAlexion Pharmaceuticals Stock Appears To Be Modestly Overvalued
gurufocus.com - July 17 at 3:36 PM
Moderna Options Traders Mixed On S&P 500 InclusionModerna Options Traders Mixed On S&P 500 Inclusion
msn.com - July 16 at 7:13 PM
When Will Moderna Be Added to the S&P 500?When Will Moderna Be Added to the S&P 500?
msn.com - July 16 at 1:48 PM
Alexions Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness DisorderAlexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder
finance.yahoo.com - July 16 at 1:48 PM
Moderna Jumps on Joining the S&P 500: What to Watch When the Stock Market Opens TodayModerna Jumps on Joining the S&P 500: What to Watch When the Stock Market Opens Today
wsj.com - July 16 at 8:22 AM
Alexion Announces Phase 3 Study Of ULTOMIRIS In Generalized Myasthenia Gravis Met Its Primary EndpointAlexion Announces Phase 3 Study Of ULTOMIRIS In Generalized Myasthenia Gravis Met Its Primary Endpoint
benzinga.com - July 15 at 10:04 PM
Moderna set to join S&P 500, stock rallies 8%Moderna set to join S&P 500, stock rallies 8%
msn.com - July 15 at 10:04 PM
Moderna to join S&P 500, shares jump after hoursModerna to join S&P 500, shares jump after hours
msn.com - July 15 at 10:04 PM
Moderna To Replace Alexion Pharma In S&P 500Moderna To Replace Alexion Pharma In S&P 500
markets.businessinsider.com - July 15 at 10:04 PM
Moderna Set to Join S&P 500Moderna Set to Join S&P 500
markets.businessinsider.com - July 15 at 7:15 PM
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
finance.yahoo.com - July 15 at 5:03 PM
Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-TermWhy Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term
finance.yahoo.com - July 15 at 12:03 PM
DateCompanyBrokerageAction
9/21/2021Regeneron PharmaceuticalsBMO Capital Markets
Boost Price Target
9/15/2021Regeneron PharmaceuticalsPiper Sandler
Boost Price Target
9/15/2021Regeneron PharmaceuticalsCantor Fitzgerald
Boost Price Target
9/15/2021Regeneron PharmaceuticalsHC Wainwright
Boost Price Target
9/9/2021Vertex PharmaceuticalsStifel Nicolaus
Downgrade
9/9/2021Regeneron PharmaceuticalsUBS Group
Initiated Coverage
9/7/2021Vertex PharmaceuticalsMorgan Stanley
Downgrade
9/7/2021Regeneron PharmaceuticalsMorgan Stanley
Boost Price Target
8/23/2021Regeneron PharmaceuticalsBenchmark
Boost Price Target
8/20/2021Regeneron PharmaceuticalsHC Wainwright
Reiterated Rating
8/9/2021Bayer AktiengesellschaftBerenberg Bank
Lower Price Target
8/6/2021Bayer AktiengesellschaftCredit Suisse Group
Reiterated Rating
8/6/2021Regeneron PharmaceuticalsBarclays
Boost Price Target
8/6/2021Regeneron PharmaceuticalsSVB Leerink
Boost Price Target
8/6/2021Regeneron PharmaceuticalsBMO Capital Markets
Boost Price Target
8/6/2021Regeneron PharmaceuticalsOppenheimer
Boost Price Target
8/5/2021Regeneron PharmaceuticalsPiper Sandler
Boost Price Target
8/4/2021Bayer AktiengesellschaftAlphaValue
Downgrade
8/2/2021Regeneron PharmaceuticalsHC Wainwright
Boost Price Target
7/30/2021Vertex PharmaceuticalsMorgan Stanley
Lower Price Target
7/30/2021Vertex PharmaceuticalsRoyal Bank of Canada
Boost Price Target
7/30/2021Vertex PharmaceuticalsSVB Leerink
Boost Price Target
7/30/2021Vertex PharmaceuticalsPiper Sandler
Boost Price Target
7/23/2021Regeneron PharmaceuticalsRoyal Bank of Canada
Boost Price Target
7/20/2021Vertex PharmaceuticalsSVB Leerink
Downgrade
7/19/2021Vertex PharmaceuticalsWolfe Research
Initiated Coverage
7/8/2021Regeneron PharmaceuticalsBenchmark
Boost Price Target
6/30/2021Vertex PharmaceuticalsRaymond James
Initiated Coverage
6/29/2021Regeneron PharmaceuticalsHC Wainwright
Initiated Coverage
6/25/2021Bayer AktiengesellschaftKepler Capital Markets
Reiterated Rating
6/14/2021Vertex PharmaceuticalsTruist
Boost Price Target
6/14/2021Vertex PharmaceuticalsPiper Sandler
Lower Price Target
6/14/2021Vertex PharmaceuticalsTruist Securities
Boost Price Target
6/14/2021Vertex PharmaceuticalsSVB Leerink
Lower Price Target
6/13/2021Vertex PharmaceuticalsEvercore ISI
Reiterated Rating
6/11/2021Vertex PharmaceuticalsStifel Nicolaus
Lower Price Target
6/11/2021Vertex PharmaceuticalsThe Goldman Sachs Group
Lower Price Target
6/11/2021Vertex PharmaceuticalsBarclays
Lower Price Target
6/11/2021Vertex PharmaceuticalsCantor Fitzgerald
Lower Price Target
6/11/2021Vertex PharmaceuticalsMorgan Stanley
Lower Price Target
6/11/2021Vertex PharmaceuticalsRobert W. Baird
Lower Price Target
6/11/2021Vertex PharmaceuticalsRoyal Bank of Canada
Lower Price Target
6/11/2021Vertex PharmaceuticalsDaiwa Capital Markets
Downgrade
5/26/2021Bayer AktiengesellschaftDZ Bank
Reiterated Rating
5/19/2021Bayer AktiengesellschaftMorgan Stanley
Reiterated Rating
5/18/2021Bayer AktiengesellschaftJPMorgan Chase & Co.
Upgrade
5/14/2021Bayer AktiengesellschaftDZ Bank
Reiterated Rating
5/13/2021Bayer AktiengesellschaftCredit Suisse Group
Reiterated Rating
5/13/2021Bayer AktiengesellschaftBryan, Garnier & Co
Upgrade
5/7/2021Regeneron PharmaceuticalsSVB Leerink
Lower Price Target
5/7/2021Regeneron PharmaceuticalsMorgan Stanley
Boost Price Target
5/5/2021Alexion PharmaceuticalsOppenheimer
Upgrade
5/3/2021Vertex PharmaceuticalsMorgan Stanley
Boost Price Target
5/3/2021Alexion PharmaceuticalsSVB Leerink
Boost Price Target
4/26/2021Vertex PharmaceuticalsMorgan Stanley
Boost Price Target
4/26/2021Alexion PharmaceuticalsCredit Suisse Group
Initiated Coverage
4/19/2021Vertex PharmaceuticalsMorgan Stanley
Boost Price Target
4/19/2021Takeda PharmaceuticalJPMorgan Chase & Co.
Downgrade
4/19/2021Regeneron PharmaceuticalsMorgan Stanley
Lower Price Target
4/13/2021Regeneron PharmaceuticalsRobert W. Baird
Reiterated Rating
4/13/2021Regeneron PharmaceuticalsCanaccord Genuity
Reiterated Rating
4/5/2021Takeda PharmaceuticalJefferies Financial Group
Downgrade
3/30/2021Bayer AktiengesellschaftDZ Bank
Reiterated Rating
3/29/2021Alexion PharmaceuticalsSVB Leerink
Reiterated Rating
3/26/2021Regeneron PharmaceuticalsSVB Leerink
Boost Price Target
3/24/2021Regeneron PharmaceuticalsCanaccord Genuity
Reiterated Rating
3/23/2021Alexion PharmaceuticalsSVB Leerink
Downgrade
3/19/2021Bayer AktiengesellschaftDeutsche Bank Aktiengesellschaft
Reiterated Rating
3/11/2021Bayer AktiengesellschaftSociete Generale
Reiterated Rating
3/4/2021Bayer AktiengesellschaftBerenberg Bank
Reiterated Rating
3/1/2021Bayer AktiengesellschaftMorgan Stanley
Reiterated Rating
3/1/2021Bayer AktiengesellschaftDZ Bank
Reiterated Rating
2/26/2021Bayer AktiengesellschaftCredit Suisse Group
Reiterated Rating
2/24/2021Regeneron PharmaceuticalsCanaccord Genuity
Reiterated Rating
2/10/2021Bayer AktiengesellschaftBarclays
Reiterated Rating
2/5/2021Alexion PharmaceuticalsSVB Leerink
Lower Price Target
2/4/2021Bayer AktiengesellschaftDZ Bank
Reiterated Rating
2/4/2021Alexion PharmaceuticalsPiper Sandler
Downgrade
1/27/2021Bayer AktiengesellschaftDeutsche Bank Aktiengesellschaft
Reiterated Rating
1/20/2021Bayer AktiengesellschaftCredit Suisse Group
Reiterated Rating
1/8/2021Bayer AktiengesellschaftMorgan Stanley
Reiterated Rating
1/8/2021Alexion PharmaceuticalsRaymond James
Downgrade
1/6/2021Bayer AktiengesellschaftNord/LB
Reiterated Rating
12/16/2020Alexion PharmaceuticalsTruist
Downgrade
12/15/2020Alexion PharmaceuticalsSmith Barney Citigroup
Downgrade
12/15/2020Alexion PharmaceuticalsRoth Capital
Boost Price Target
12/14/2020Alexion PharmaceuticalsSVB Leerink
Boost Price Target
12/14/2020Alexion PharmaceuticalsRobert W. Baird
Downgrade
12/14/2020Alexion PharmaceuticalsWedbush
Downgrade
12/14/2020Alexion PharmaceuticalsRoyal Bank of Canada
Boost Price Target
12/14/2020Alexion PharmaceuticalsBMO Capital Markets
Downgrade
12/14/2020Alexion PharmaceuticalsCredit Suisse Group
Downgrade
11/19/2020Alexion PharmaceuticalsSanford C. Bernstein
Initiated Coverage
11/6/2020Bayer AktiengesellschaftMorgan Stanley
Reiterated Rating
11/5/2020Bayer AktiengesellschaftDeutsche Bank Aktiengesellschaft
Reiterated Rating
11/5/2020Alexion PharmaceuticalsSmith Barney Citigroup
Boost Price Target
11/5/2020Alexion PharmaceuticalsRoyal Bank of Canada
Reiterated Rating
10/30/2020Alexion PharmaceuticalsSvb Leerink
Lower Price Target
10/30/2020Alexion PharmaceuticalsSVB Leerink
Boost Price Target
10/30/2020Alexion PharmaceuticalsMorgan Stanley
Lower Price Target
10/29/2020Alexion PharmaceuticalsPiper Sandler
Boost Price Target
10/28/2020Alexion PharmaceuticalsUBS Group
Initiated Coverage
3/11/2020Takeda PharmaceuticalJPMorgan Chase & Co.
Lower Price Target
11/1/2019Takeda PharmaceuticalCowen
Initiated Coverage
9/24/2019Takeda PharmaceuticalJefferies Financial Group
Initiated Coverage
8/15/2019Takeda PharmaceuticalDaiwa Capital Markets
Downgrade
3/19/2019Takeda PharmaceuticalThe Goldman Sachs Group
Reiterated Rating
(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.